Neuralstem Inc. shares (NYSE:CUR) crumpled on Thursday, falling 36.6 percent in heavy trading to close at $2.37 as investors mulled top-line data from a phase II dose-escalation trial of NSI-566, the company's experimental neural stem cell therapy for amyotrophic lateral sclerosis (ALS).